Overview

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Status:
COMPLETED
Trial end date:
2024-10-24
Target enrollment:
Participant gender:
Summary
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
Phase:
NA
Details
Lead Sponsor:
Affiliated Hospital of Jiangnan University